This Harvard-wide Program on Antibiotic Resistance (HPAR) proposal outlines the design and function of a novel, interdisciplinary, collaborative partnership to develop and test new validated lead compounds for changing the paradigms for treatment of multidrug resistant MRSA, VRE and now VRSA infections. Although discovery and delivery of novel and promising new compounds to the development pipeline is a major overall goal, because this is an academic effort, adding to the base of scientific knowledge that underpins the development of inhibitors for these pathogens;the understanding of resistance, and development of novel new tools for studying host-pathogen interactions and multidrug resistant pathogens are also major goals. This project is being proposed by an accomplished group of scientists with extensive experience in the biochemistry of cell wall biosynthesis and use of that information to design screens and new inhibitors;the molecular biology of model host systems and the use of those systems in novel ways for screening compounds that block the ability of bacteria to harm the host;the biology and molecular genetics of biofilm formation in model systems and the use of that information to identify biofilm disrupting agents;the pathogenesis, genetics and antibiotic resistance of enterococci;and the pathogenesis, molecular biology and clinical treatment of infection caused by multidrug resistant staphylococci. This scientific expertise is complemented by administrative experience that includes service as university Vice President for Research, and President and CEO of a research institute. The goal of the HPAR Administrative Core is to create a cohesive and well functioning whole that is greater than the sum of the individual projects.
The Specific Aims of the Administrative Core are to 1) Provide program management and oversight, 2) Facilitate interactions between participants from the various components of Harvard University, 3) Provide critical infrastructure for fiscal management of the program;4) Provide connectivity to and leverage from other Harvard-wide initiatives;and 5) Provide a single point of contact and active coordination for on-going communication with NIAID and the Program Officer, and other NIAID initiatives.

Public Health Relevance

MRSA infections are common, often invasive and life threating. VRE are leading causes of hospital acquired infection. VRE now have donated vancomycin resistance to MRSA, creating VRSA refractor to this last line antibiotic. The administrative core will assure the smooth operation of this PPG, and will insure that the products generated are much greater than the sum of its parts.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI083214-07
Application #
8716648
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
7
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Massachusetts Eye and Ear Infirmary
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02114
Lee, Wonsik; Do, Truc; Zhang, Ge et al. (2018) Antibiotic Combinations That Enable One-Step, Targeted Mutagenesis of Chromosomal Genes. ACS Infect Dis 4:1007-1018
Zhai, Hualei; Bispo, Paulo J M; Kobashi, Hidenaga et al. (2018) Resolution of fluoroquinolone-resistant Escherichia coli keratitis with a PROSE device for enhanced targeted antibiotic delivery. Am J Ophthalmol Case Rep 12:73-75
Yuen, Grace J; Ausubel, Frederick M (2018) Both live and dead Enterococci activate Caenorhabditis elegans host defense via immune and stress pathways. Virulence 9:683-699
Wurster, Jenna I; Bispo, Paulo J M; Van Tyne, Daria et al. (2018) Staphylococcus aureus from ocular and otolaryngology infections are frequently resistant to clinically important antibiotics and are associated with lineages of community and hospital origins. PLoS One 13:e0208518
Keohane, Colleen E; Steele, Andrew D; Fetzer, Christian et al. (2018) Promysalin Elicits Species-Selective Inhibition of Pseudomonas aeruginosa by Targeting Succinate Dehydrogenase. J Am Chem Soc 140:1774-1782
Majed, Hiwa; Johnston, Tatiana; Kelso, Celine et al. (2018) Structure-activity relationships of pyrazole-4-carbodithioates as antibacterials against methicillin-resistant Staphylococcus aureus. Bioorg Med Chem Lett 28:3526-3528
Slatko, Barton E; Gardner, Andrew F; Ausubel, Frederick M (2018) Overview of Next-Generation Sequencing Technologies. Curr Protoc Mol Biol 122:e59
Tiwari, Kiran B; Gatto, Craig; Walker, Suzanne et al. (2018) Exposure of Staphylococcus aureus to Targocil Blocks Translocation of the Major Autolysin Atl across the Membrane, Resulting in a Significant Decrease in Autolysis. Antimicrob Agents Chemother 62:
Zhang, Sicai; Lebreton, Francois; Mansfield, Michael J et al. (2018) Identification of a Botulinum Neurotoxin-like Toxin in a Commensal Strain of Enterococcus faecium. Cell Host Microbe 23:169-176.e6
Santiago, Marina; Lee, Wonsik; Fayad, Antoine Abou et al. (2018) Genome-wide mutant profiling predicts the mechanism of a Lipid II binding antibiotic. Nat Chem Biol 14:601-608

Showing the most recent 10 out of 145 publications